BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Drugmakers Like Roche (RHHBY) and GlaxoSmithKline (GSK) Bet on New Blockbusters in 2013


1/15/2013 6:37:22 AM

Drugmakers are betting that a new wave of medicines for cancer, diabetes, heart disease, multiple sclerosis and hepatitis will shape up as tomorrow's blockbusters in the coming 12 months. With the industry regaining some of its swagger after winning 39 new drug approvals last year - a record only beaten in 1996 - there are signs the improving trend could continue through 2013. Roche, GlaxoSmithKline, Eli Lilly, Biogen Idec, Gilead Sciences and Novo Nordisk are among those with important new products reaching a critical point in development this year. The industry needs a winning streak after delivering poor returns for years due to a wave of patent expiries. Now companies are emerging from that patent "cliff" and the balance of losses to new opportunities is improving. European drugmakers, for example, have the potential to deliver new drugs from 2013 to 2015 with peak annual sales of $64 billion (or $27 billion after adjusting for the risk of failure), while fresh patent losses in the period will be only $12 billion, according to Deutsche Bank estimates. Simon Friend, global pharmaceutical leader at PricewaterhouseCoopers, agrees the picture is improving. But he warns it is still too early to say that drug companies are out of the woods, especially with governments and insurers taking an increasingly tough line on paying for new medicines. "Productivity is starting to turn the corner - but the other big issue is whether the industry can get the prices it needs for new products," he said. Still, analysts say interest in the sector from growth funds is now picking up and investors are taking a closer look at drug BIOGEN AIMS FOR BEST IN CLASS A number of key research and development bets on potential multibillion-dollar-a-year products will play out in 2013. One of the most highly anticipated approvals of the year, likely to come in the first quarter, is for Biogen's multiple sclerosis (MS) drug BG-12.

Read at Reuters

Reuters
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES